We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Adjuvants for Immunotherapy and Vaccine Development

Adjuvants for Immunotherapy and Vaccine Development content piece image

Whether you specialize in lipidomics, or lipids are a regular part of your research, you will know the critical role they play. For example, adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595, have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. While adjuvant systems play a key part in immunotherapy and vaccine development programs, adjuvant formulation can be a costly and time-consuming process. Partnering with a company with expertise in lipid formulation can help to relieve this burden.

Download this flyer to discover:

  • Various monophosphoryl lipid A (MPLA) adjuvants
  • A trehalose dibehenate and DDA adjuvant system for tuberculosis vaccines